USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ANJIN GROUP, INC.
Address:
10 CHILHOWIE CT.
COCKEYSVILLE, MD 21030 2202
Phone:
N/A
URL:
N/A
EIN:
20669751
DUNS:
143606742
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $567,216.00 4

Award List:

An IL-2 Receptor Targeted Toxin with Reduced VLS

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$144,786.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Well over a decade ago the first diphtheria toxin-based fusion protein toxin, DAB389IL-2 (Ontak(R)) was in development as the first of a new class of receptor specific therapeutic agent. This fusion protein gained FDA approval five years ago for the treatment of… More

Modified Diphtheria Toxin IL-7 Fusion Toxins

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$152,141.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Sweeney et al. (1998) originally reported the construction of DAB389IL-7, a fusion protein based on diphtheria toxin (DT), and proposed that this fusion protein could be employed as a therapeutic agent for hematological malignancies, including acute lymphoblastic… More

Generation of a Modified DT_IL3 Fusion Toxin

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$122,830.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): A number of protein fusion toxins, composed of the diphtheria toxin (DT) toxophore and a targeting ligand, have been assembled and tested in Phase I clinical trials for the treatment of leukemias. To date, the only FDA approved protein fusion toxin is ONTAK.… More

Further Analysis of a VLS Modified IL-2 Receptor Targeted Toxin

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$147,459.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The project seeks to further the development of a series of diphtheria toxin mutants which, when employed in the construction of protein fusion toxins, display reduced induction of leakage through vascular endothelial c ell monolayers. The goals of this Phase I… More